President Donald Trump announced a 100% tariff on imported generic pharmaceutical drugs on Tuesday. Set to take effect in August 2028, the phased schedule is intended to bolster domestic pharmaceutical production and push generic drugmakers to move production onshore. This move represents a major expansion of a strategy the president has employed against the pharmaceutical industry since the start of his second term.
Although the administration has repeatedly stated it would impose steep pharmaceutical tariffs without following through in the past, this current plan indicates that imported generic medicines could face tariffs of up to 200% after two years. Because specific details remain unclear, the plan raises questions over prices, U.S. manufacturing, and which drugmakers stand to gain or lose.
Health policy experts warn that the proposed tariffs could have far-reaching consequences for the cost and availability of medications. Experts suggest that higher import duties could increase costs and strain supplies while offering no guarantee that manufacturers will shift production to the U.S. Additionally, an industry group noted that the generic drug market still faces structural and purchasing hurdles despite strong U.S. growth.